Logo
x

Search

Subscribe Now

ImmunoGen

ImmunoGen Collaborates with Takeda to Develop and Commercialize Elahere to Treat Platinum-Resistant Ovarian Cancer in Japan

ImmunoGen Collaborates with Takeda to Develop and Commercialize Elahere to Treat Platinum-Resistant Ovarian Cancer in Japan

  • August 28, 2023
ImmunoGen Entered into a Multi-Target License and Option Agreement with ImmunoBiochem to Develop Antibody-Drug Conjugates

ImmunoGen Entered into a Multi-Target License and Option Agreement with ImmunoBiochem to Develop Antibody-Drug Conjugates

  • July 24, 2023
ImmunoGen Reports P-III Trial (MIRASOL) Results of Elahere (mirvetuximab soravtansine) for FRα-Positive Platinum-Resistant Ovarian Cancer

ImmunoGen Reports P-III Trial (MIRASOL) Results of Elahere (mirvetuximab soravtansine) for FRα-Positive Platinum-Resistant Ovarian...

  • May 5, 2023
ImmunoGen Signs a Multi-Target License and Option Agreement with Vertex to Develop Novel Targeted Conditioning Agents

ImmunoGen Signs a Multi-Target License and Option Agreement with Vertex to Develop Novel Targeted Conditioning Agents

  • March 2, 2023
Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

  • March 11, 2021
PharmaShots Weekly Snapshot (Oct 19 - 23, 2020)

PharmaShots Weekly Snapshot (Oct 19 - 23, 2020)

  • October 23, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.